Compared to dispersible L-Dopa (3.5 mg/kg) combined with the dopa-decarboxylase inhibitor benserazide (DDCI), it was found that low doses of M. pruriens (12.5 mg/kg) exhibited a similar motor response, with fewer dyskinesias and adverse events (disruptions in blood pressure and heart rate and severity of dyskinesias); high doses (17.5 mg/kg) induced more significant motor improvement at 90 and 180 min, with a longer duration, fewer dyskinesias, and fewer adverse events [17]. The gene discussed is DDC; the disease is drug-induced dyskinesia.